Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey


Creative Commons License

Dal M. S., Ulu B. U., UZAY A., Akay O. M., Besisik S., Yenerel M. N., ...More

ANNALS OF HEMATOLOGY, vol.102, no.1, pp.133-140, 2023 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 102 Issue: 1
  • Publication Date: 2023
  • Doi Number: 10.1007/s00277-022-05052-x
  • Journal Name: ANNALS OF HEMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.133-140
  • Keywords: Diffuse large B-cell lymphoma, Polatuzumab vedotin, Refractory, Relapsed, Rituximab, Bendamustine, ANTIBODY-DRUG CONJUGATE, NON-HODGKIN-LYMPHOMA, PLUS BENDAMUSTINE, SURVIVAL, SAFETY
  • Istanbul University Affiliated: Yes

Abstract

Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.8 mg/kg, rituximab 375 mg/m(2) on day 1, and bendamustine 90 mg/m(2) on days 1-2 of each cycle. Median age at Pola-BR initiation was 55 (19-84). The overall response rate was 47.9%, including 32.4% CR rate when a median of 3 cycles was applied. With a median follow-up of 5 months, the median OS was 5 months. Grade 3-4 neutropenia and thrombocytopenia were the most common hematological toxicities. The real-world data from our cohort showed the Pola-BR is an effective option with a manageable toxicity profile.